MK-1084

Merck Launches Phase III Study for KRAS Hopeful, Eyes Challenge to Amgen and BMS
BioSpace
Fri, 04/5/24 - 11:42 am
Merck
clinical trials
KRAS inhibitors
MK-1084
non-small lung cancer